<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473043</url>
  </required_header>
  <id_info>
    <org_study_id>A4061061</org_study_id>
    <nct_id>NCT01473043</nct_id>
  </id_info>
  <brief_title>Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment</brief_title>
  <official_title>Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell
      variant), who have failed first line therapy. The study will recruit a maximum of 30 patients
      from 2 countries including Australia and Canada. Patients will be followed up for efficacy,
      safety and health related outcomes.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Expanded Access</study_type>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol</description>
    <other_name>AG-013736</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic renal cell carcinoma with a component of clear cell subtype.

          -  Prior first line systemic therapy

          -  At least 1 measurable lesion as per Response Evaluation Criterion in Solid Tumors
             [RECIST 1.1].

          -  Adequate hematology, liver and kidney functions

          -  Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1.

          -  Life expectancy of â‰¥12 weeks.

          -  Normotensive or well controlled hypertension (less than/equal to 140/90 mm Hg.)

          -  Negative pregnancy test

          -  Adequate recovery time from prior systemic therapy, surgery or radiation

          -  Willing and able subjects who have signed consent

        Exclusion Criteria:

          -  More than one prior systemic therapy regimen

          -  Major bowel-penetrating surgery &lt;4 weeks

          -  Active gastro intestinal bleed in past 3 months

          -  Active peptic ulcer disease in the past 6 months

          -  Current or anticipated use of potent CYP3A4/5 inhibitors

          -  Current or anticipated use of known CYP3A4/5 or CYP1A2 inducers

          -  Requirement for therapeutic warfarin or high dose steroids

          -  Symptomatic or untreated brain metastases

          -  A serious uncontrolled medical disorder or active infection

          -  Pregnant or breastfeeding females

          -  History of another active malignancy

          -  Dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wendouree</city>
        <state>Victoria</state>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061061&amp;StudyName=Clinical%20Study%20With%20Axitinib%20In%20Advanced%20Kidney%20Cancer%2C%20Who%20Have%20Failed%20First%20Line%20Treatment%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axitinib</keyword>
  <keyword>metastatic renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

